Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

Arthritis and Rheumatism

Volumn 50, Issue 6, 2004, Pages 1740-1751

  Wolfe, Frederick ^a,c   Michaud, Kaleb ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DRUG EFFECT; EDUCATION; FEMALE; FOLLOW UP; GENDER; HEALTH SURVEY; HUMAN; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SEER PROGRAM; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2642554059     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20311     Document Type: Article

References (76)

1. National Cancer Institute. Surveillance, Epidemiology and End Results page. URL: http://seer.cancer.gov/.
2. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A: 1753-7.
3. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
4. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
5. Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol 1982;11:81-6.
6. Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985;78:50-5.
7. Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43: 128-31.
8. Laakso M, Mutru O, Isomaki HA, Koota K. Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 1986;13:522-6.
9. Tennis P, Andrews E, Bombardier C, Wang Y, Strand L, West R, et al. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada. J Clin Epidemiol 1993;46:685-95.
10. Tennis P, Bombardier C, Malcolm E, Downey W. Validity of rheumatoid arthritis diagnoses listed in the Saskatchewan Hospital Separations Database. J Clin Epidemiol 1993;46:675-83.
11. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
12. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 1998;317:180-1.
13. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients. Arthritis Rheum 1998;41 Suppl 9:S188.
14. Newkirk MM, Shiroky JB, Johnson N, Danoff D, Isenberg DA, Shustik C, et al. Rheumatic disease patients, prone to Sjögren's syndrome and/or lymphoma, mount an antibody response to BHRF1, the Epstein-Barr viral homologue of BCL-2. Br J Rheumatol 1996;35:1075-81.
15. Van de Rijn M, Cleary ML, Variakojis D, Warnke RA, Chang PP, Kamel OW. Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis. Arthritis Rheum 1996;39: 638-42.
16. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26: 1676-80.
17. Urowitz MB, Lee P. The risks of antimalarial retinopathy, azathioprine lymphoma and methotrexate hepatotoxicity during the treatment of rheumatoid arthritis. Baillieres Clin Rheumatol 1991;4:193-206.
18. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988;47:988-92.
19. Pitt PI, Sultan AH, Malone M, Andrews V, Hamilton EB. Association between azathioprine therapy and lymphoma in rheumatoid disease. J R Soc Med 1987;80:428-9.
20. Hazleman BL. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis 1982;41 Suppl 1:12-7.
21. Van Wanghe P, Dequeker J. Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases. Ann Rheum Dis 1982;41 Suppl 1:40-3.
22. Cobeta-Garcia JC, Ruiz-Jimeno MT, Fontova-Garrofe R. Non-Hodgkin's lymphoma, rheumatoid arthritis and methotrexate. J Rheumatol 1993;20:200-2.
23. Kamel OW, Vanderijn M, Weiss LM, Delzoppo GJ, Hench PK, Robbins BA, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
24. Morris CR, Morris AJ. Localized lymphoma in a patient with rheumatoid arthritis treated with parenteral methotrexate. J Rheumatol 1993;20:2172-3.
25. Shiroky JB, Newkirk MM. Reversible lymphomas. N Engl J Med 1993;329:1657-8.
26. Taillan B, Garnier G, Castanet J, Ferrari E, Pesce A, Dujardin P. Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate. Clin Rheumatol 1993;12:93-4.
27. Buskila D, Thomson GT, Klein M, Keystone EC. Avascular necrosis of bone mimicking symmetric polyarthritis in a patient with malignant lymphoma treated with high-dose steroids. Isr J Med Sci 1992;28:804-5.
28. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 1992;19: 1462-5.
29. Klein HP. Occurrence of highly malignant non-Hodgkin's lymphoma in correlation with Imurek therapy and later MTX therapy of chronic polyarthritis. Z Rheumatol 1992;51:256-9.
30. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 1991;18:1741-3.
31. Thomson GT, Keystone EC, Sturgeon JF, Fornasier V. Erythema nodosum and non-Hodgkin's lymphoma. J Rheumatol 1990;17: 383-5.
32. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15.
33. Starkebaum G. Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus? J Rheumatol 2001;28:2573-5.
34. Georgescu L, Paget SA. Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? Drug Saf 1999;20:475-87.
35. Kono H, Inokuma S, Matsuzaki Y, Nakayama H, Yamazaki J, Hishima T, et al. Two cases of methotrexate induced lymphomas in rheumatoid arthritis: an association with increased serum IgE. J Rheumatol 1999;26:2249-53.
36. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26: 794-804.
37. Sukenik S, Ariad S, Flusser D. Malignancy in patients with rheumatoid arthritis treated with methotrexate [letter]. J Rheumatol 1997;24:806.
38. Usman AR, Yunus MB. Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. J Rheumatol 1996;23:1095-7.
39. Viraben R, Brousse P, Lamant L. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br J Dermatol 1996;135: 116-8.
40. Kerr LD, Troy K, Isola L. Temporal association between the use of methotrexate and development of leukemia in 2 patients with rheumatoid arthritis. J Rheumatol 1995;22:2356-8.
41. Marlier S, Chagnon A, Brocq O, de Jaureguiberry JP, Jaubert D, Paris JF, et al. Lymphoma induced by low-dose methotrexate in rheumatoid arthritis with severe lymphopenia. Ann Med Interne (Paris) 1995;146:206-8.
42. Brackertz D. Occurrence of a highly malignant non-Hodgkin lymphoma in connection with azathioprine therapy and methotrexate therapy in a patient with rheumatoid arthritis. Z Rheumatol 1992;51:257-9.
43. Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 1991;18:1172-5.
44. Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: Report of two cases. Arthritis Rheum 1996;39:325-9.
45. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943-9.
46. Liote F, Pertuiset E, Cochand-Priollet B, D'Agay MF, Dombret H, Numeric P, et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis: role of Epstein-Barr virus infection. J Rheumatol 1995;22:1174-8.
47. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995;99:276-81.
48. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738-45.
49. Van den Borne BE, Landewé RB, Houkes I, Schild F, van der Heyden PC, Hazes JM, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1930-7.
50. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published erratum appears in N Engl J Med 2001;344:240]. N Engl J Med 2000;343: 1586-93.
51. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published erratum appears in N Engl J Med 2001;344:240]. N Engl J Med 2000;343: 1586-93.
52. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al, and the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337: 1029-35.
53. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
54. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
55. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
56. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
57. FDA. Briefing Document. US Food and Drug Administration: 2003.
58. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002;29:467-73.
59. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002;29:1015-22.
60. Wolfe F, Flowers N, Anderson J. The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice. Arthritis Rheum 1998;41 Suppl 9:S132.
61. Fries JF, Spitz PW, Young DY. The dimensions of health out-comes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
62. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
63. Hawley DJ, Wolfe F. Depression is not more common in rheumatoid arthritis: a 10-year longitudinal study of 6,153 patients with rheumatic disease. J Rheumatol 1993;20:2025-31.
64. Hawley DJ, Wolfe F. Anxiety and depression in patients with rheumatoid arthritis: a prospective study of 400 patients. J Rheumatol 1988;15:932-41.
65. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
66. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
67. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997;36: 786-93.
68. Choi HK, Michaud K, Wolfe F. Utility measures in rheumatic disorders [abstract]. Arthritis Rheum 2002;46 Suppl 9;S76.
69. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21: 271-92.
70. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-28.
71. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
72. Doody MM, Hayes HM, Bilgrad R. Comparability of national death index plus and standard procedures for determining causes of death in epidemiologic studies. Ann Epidemiol 2001;11:46-50.
73. Edlavitch SA, Baxter J. Comparability of mortality followup before and after the National Death Index. Am J Epidemiol 1988;127:1164-78.
74. Stata statistical software: release 8.0. College Station (TX): Stata Corporation; 2003.
75. Wolfe F, Pincus T, O'Dell J. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. J Rheumatol 2001;28:1712-7.
76. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate therapy and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.